Elucidating the Phase I metabolism of psilocin in vitro.
Junqi Chen, Ziteng Wang, Ching Yee Yong, Evelyn Mei Ling Goh, Hooi Yan Moy, Eric Chun Yong Chan
Archives of toxicology March 1, 2025 DOI: 10.1007/s00204-024-03952-7 via PubMed
Summary
AI-generated from the abstractPsilocin, the active compound from magic mushrooms, is metabolized mainly by the enzyme monoamine oxidase A (MAO-A) in the liver and other organs. The Phase I metabolic pathway produces a newly identified intermediate, 2-(4-hydroxy-1H-indol-3-yl)-acetaldehyde (4-HIA), which is then converted to the terminal metabolite 2-(4-hydroxy-1H-indol-3-yl)-acetic acid (4-HIAA) by aldehyde oxidase and aldehyde dehydrogenases. MAO-A-mediated hepatic clearance accounts for 80.9% of total hepatic metabolism, but extrahepatic clearance is substantial, with total MAO-A-mediated organ clearance estimated at 614.81 mL/min, indicating that MAO-A plays a major role both in the liver and elsewhere in the body.
Study at a glance
| Characteristics | In vitro study Peer reviewed |
|---|---|
| Population | Human enzymes |
| Intervention | psilocin |
| Topics | Psilocybin |
| Keywords | Metabolic pathways Biotransformation Hallucinogens Psychedelic compounds |
| Citations | 3 |
| Key finding | MAO-A is the primary enzyme responsible for psilocin's Phase I metabolism, producing the intermediate 4-HIA, and contributes extensively to both hepatic and extrahepatic clearance. |
Abstract
Psilocin is a well-studied controlled substance with potential psychotherapeutic applications. However, research gaps remain regarding its metabolism. Our objective was to elucidate a comprehensive Phase I metabolic profile of psilocin to support its forensic management and clinical development. We utilized human enzymes from various sources to characterize the Phase I metabolism of psilocin and estimated its hepatic and extrahepatic clearances via in vitro to in vivo extrapolation. We identified 2-(4-hydroxy-1H-indol-3-yl)-acetaldehyde (4-HIA) as the Phase I intermediate metabolite for the first time. Psilocin was metabolized to 4-HIA by monoamine oxidase A (MAO-A), and further metabolized to the terminal metabolite 2-(4-hydroxy-1H-indol-3-yl)-acetic acid (4-HIAA) by cytosolic aldehyde oxidase (AO) and aldehyde dehydrogenases (ALDHs). MAO-A-mediated hepatic clearance of psilocin (CLH,MAO-A) was estimated to be 158.74 mL/min, accounting for 80.9% of the total hepatic metabolism of psilocin (CLH,all). MAO-A primarily contributed to the Phase I metabolism of psilocin. Total MAO-A-mediated organ clearance (CLall organs,MAO-A) was estimated to be 614.81 mL/min, with CLH,MAO-A accounting for 25.8%, indicating extensive MAO-A-mediated extrahepatic clearance of psilocin. Overall, our study sheds novel insights on Phase I metabolic pathway of psilocin and illuminated the importance of MAO-A-mediated hepatic and extrahepatic clearances of psilocin.